

**The BeyoND study: Design and baseline characteristics of an international, multicentre study evaluating the long-term safety of ND0612 for Parkinson's disease**

**Werner Poewe**

Medical University Innsbruck, Innsbruck, Austria

Fabrizio Stocchi, Alberto Espay, Sheila Oren, Cecile Durlach,  
Karl Kieburtz, C. Warren Olanow

## Speaker disclosures

Werner Poewe reports receiving consulting fees from AbbVie, Allergan, Astra Zeneca, BIA, Boehringer-Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, NeuroDerm, Novartis, Orion Pharma, Teva, UCB and Zambon.

This study was sponsored by NeuroDerm


# ND0612 infusion in Parkinson's disease patients with motor fluctuations

## Background

- Continuous LD/CD infusion is considered the optimal delivery route for treating advanced motor fluctuations because it avoids the peaks and troughs associated with oral dosing
  - Utility of infusion strategies has thus far been limited by the need for invasive surgery
- ND0612 is a drug-device combination that *continuously* delivers *liquid LD/CD subcutaneously* through a pump system
- Phase II clinical studies in PD patients with motor fluctuations have shown a *clinically meaningful and statistically significant reduction in OFF time* without an increase in troublesome dyskinesia

**The aim of this Phase 2b/3 study is to assess the long-term safety (systemic and local) and tolerability of continuous subcutaneous infusion of ND0612**

# ND0612 BeyoND Study: Design



# ND0612 BeyoND Study: *Inclusion/exclusion criteria\**

Key inclusion criteria	Key exclusion criteria
PD patients aged 30-85 years old	Previously unable to tolerate ND0612, regardless of the dosing regimen administered (previously treated patients only)
Modified Hoehn & Yahr scale $\leq 3$ during ON	Atypical or secondary parkinsonism.
$\geq 2$ hours of OFF time per day with predictable early morning OFF periods	Acute psychosis or hallucinations in past 6 months
Taking $\geq 4$ levodopa doses/day ( $\geq 3$ doses/day of Rytary)	Any relevant medical, surgical, or psychiatric condition
Taking, or have attempted to take, $\geq 1$ other PD treatment for $\geq 30$ days in the previous year	Prior neurosurgical procedure for PD or LCIG treatment
	Clinically significant ECG rhythm abnormalities

*\*Rollover patients met these criteria at the start of the prior ND0612 study*

# ND0612 BeyoND Study: Assessments

Safety and tolerability	Efficacy (exploratory outcomes)
AE reporting	Daily OFF time based on home diaries
Local skin safety at infusion site	Good ON time (no or non-troublesome dyskinesia)
Tolerability: <ul style="list-style-type: none"><li>- % patients completing 12 months of treatment</li><li>- % patients discontinuing from the 12-month treatment period due to an AE</li></ul>	Total daily dose of oral levodopa therapy
	UPDRS ADL and motor scores
	PDQ-39
	CGI for severity and improvement
Vital signs, physical and neurological examination	Parkinson's disease sleep scale (PDSS)

# ND0612 BeyoND Study: *Baseline characteristics*

Characteristic	(N=209)
Percent male	66%
Age (years); mean $\pm$ SD	64.1 $\pm$ 8.76
Time from diagnosis (years); mean $\pm$ SD	9.02 $\pm$ 4.70
Time with motor fluctuations (years); mean $\pm$ SD	5.23 $\pm$ 4.20
Duration of daily OFF time (hours); mean $\pm$ SD	5.47 $\pm$ 2.72
UPDRS motor score; mean $\pm$ SD	27.4 $\pm$ 12.5
MMSE score; mean $\pm$ SD	28.8 $\pm$ 1.2
Levodopa dose (mg); mean $\pm$ SD	1060 $\pm$ 665
N (%) patients taking $\geq$ 900mg LD/day	109 (52.2%)
Use of COMT inhibitor; N (%)	54 (25.8)

## ND0612 BeyoND Study: *Take Home Messages*

- The BeyoND Study is the first study to evaluate the long-term safety of high dose ND0612
- The demographics in the study are typical to those with Parkinson's disease experiencing motor fluctuations despite optimal use of oral therapies
- Recruitment is complete and the trial is ongoing. Twelve-month data are expected by December 2019.
- A phase 3 double-blind, double-dummy pivotal efficacy trial (BouNDless) is currently being initiated to evaluate ND0612 in a similar population